Engineering and Development

Management and Executive

Legal and Compliance

Customer Service and Support

Corp. SVP BioPharma Network

Corporate Vice President

Mars, Hill’s, Zoetis Join HABRI to Chart Path Toward Sustainable Future for Veterinary Medicine

Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market Forecasts Report 2025-2030 | Boehringer Ingelheim and FibroGen Lead by Driving Innovations in Pharmacological and Diagnostic Advancements

FDA grants Hernexeos ‘Breakthrough’ status in NSCLC

Urea Cycle Disorder Treatment Market Outlook 2035: Rising to US$ 771 Mn at 3.5% CAGR | Transparency Market Research

ED, Early Asset Lead - Antibody Drug Conjugates

Boehringer Ingelheim is a global leader in the pharmaceutical industry, and they are seeking an Early Asset Lead for Antibody Drug Conjugates. The role involves driving early clinical development projects, leading cross-functional teams, and ensuring the implementation of high-quality clinical development plans.

ED, Early Asset Lead - Antibody Drug Conjugates (Remote)

Former Head of Research and Development Animal Health

Director, Biologics CMC Research

Sr. Associate Director, Translational Research and Biomarkers (Bacterial Diseases)

Director, External Alternative CMC Development (EACD)

Executive Director and Head of Drug Concept Discovery, I&R

Sign up with Google

Sign in with Google